Document is current
Any future updates will be listed below
-
Authors
Gong, Tong https://orcid.org/0000-0002-6887-9432
Kuja-Halkola, Ralf https://orcid.org/0000-0002-3765-2067
Harder, Arvid
Lundholm, Cecilia
Smew, Awad I. https://orcid.org/0000-0002-4653-6615
Lehto, Kelli
Andreasson, Anna https://orcid.org/0000-0003-0203-7977
Lu, Yi https://orcid.org/0000-0001-9933-3654
Talley, Nicholas J. https://orcid.org/0000-0003-2537-3092
Pasman, Joëlle A.
Almqvist, Catarina https://orcid.org/0000-0002-1045-1898
Brew, Bronwyn K. https://orcid.org/0000-0002-9885-8261
-
Funding
Funding for this research was provided by:
Vetenskapsrådet (2018-02640, 2023-02327)
Karolinska Institutet (2020-0007 & 2022-02303)
- License Information
-
More Information
Article History
Received: 13 March 2023
Accepted: 28 August 2024
First Online: 2 September 2024
Competing interests
: The authors have no conflict of interest to declare except for Professor Nicholas Talley (NJT). NJTs involvement is all outside the submitted work: Norgine (2021)(IBS interest group), personal fees from Allakos (gastroduodenal eosinophilic disease) (2021), twoXAR Viscera Labs, (USA 2021) (IBS-diarrhea), IsoThrive (2021) (esophageal microbiome), BluMaiden (microbiome advisory board) (2021), Rose Pharma (IBS) (2021), Intrinsic Medicine (2022) (human milk oligosaccharide), Comvita Mānuka Honey (2021) (digestive health), Astra Zeneca (2022). In addition, Dr. Talley has a patent Nepean Dyspepsia Index (NDI) 1998, a patent Licensing Questionnaires Talley Bowel Disease Questionnaire licensed to Mayo/Talley, “Diagnostic marker for functional gastrointestinal disorders” Australian Provisional Patent Application 2021901692, ”Methods and compositions for treating age-related neurodegenerative disease associated with dysbiosis” US Application No. 63/537,725.
